Vega Jovaní

Dr. Vega Jovaní

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LSLara Sanchez-Bilbao
Lara Sanchez-Bilbao
DMDavid Martínez-López
David Martínez-López
MRMarcelino Revenga
Marcelino Revenga
ÁLÁngel López-Vázquez
Ángel López-Vázquez
EVElia Valls-Pascual
Elia Valls-Pascual
RBRicardo Blanco
Ricardo Blanco
Graves’ orbitopathy (GO) is the most common extrathyroidal manifestation of Graves’ disease (GD). Our aim was to assess the efficacy and safety of Tocilizumab (TCZ) in GO refractory to conventional therapy. This was an open-label multicenter study of glucocorticoid-resistant GO treated with TCZ. The main outcomes were the best-corrected visual acuity (BVCA), Clinical Activity Score (CAS) and intraocular pressure (IOP). These outcome variables were assessed at baseline, 1st, 3rd, 6th and 12th month after TCZ therapy onset. The severity of GO was assessed according to the European Group on Graves’ Orbitopathy (EUGOGO). We studied 48 (38 women and 10 men) patients (95 eyes); mean age ± standard deviation 51 ± 11.8 years. Before TCZ and besides oral glucocorticoids, they had received IV methylprednisolone (n = 43), or selenium (n = 11). GO disease was moderate (n =29) or severe (n = 19) and dysthyroid optic neuropathy (DON) (n = 7). TCZ was used in monotherapy (n = 45) or combined (n = 3) at a dose of 8 mg/kg IV every four weeks (n = 43) or 162 mg/s.c. every week (n = 5). TCZ yielded a significant improvement in all of the main outcomes at the 1st month that was maintained at one year. Comparing the baseline with data at 1 year all of the variables improved; BCVA (0.78 ± 0.25 vs. 0.9 ± 0.16; p = 0.0001), CAS (4.64 ± 1.5 vs. 1.05 ± 1.27; p = 0.0001) and intraocular pressure (IOP) (19.05 ± 4.1 vs. 16.73 ± 3.4 mmHg; p = 0.007). After a mean follow-up of 16.1 ± 2.1 months, low disease activity (CAS ≤ 3), was achieved in 88 eyes (92.6%) and TCZ was withdrawn in 29 cases due to low disease activity (n = 25) or inefficacy (n = 4). No serious adverse events were observed. In conclusion, TCZ is a useful and safe therapeutic option in refractory GO treatment.

12 October 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
VJVega Jovaní
Vega Jovaní
MBMar Blasco-Blasco
Mar Blasco-Blasco
EPEliseo Pascual
Eliseo Pascual
MRM Teresa Ruiz-Cantero
M Teresa Ruiz-Cantero
Diagnostic delay is well-known in spondyloarthritis and studies have demonstrated a longer deferral in women. The aim of this study was to explore whether diagnostic delay of spondyloarthritis depends on clinical manifestations expressed by patients according to sex or whether it is related to a doctor’s misdiagnosis bias. A cross-sectional study of 96 men and 54 women with spondyloarthritis was performed at Alicante University General Hospital in Spain using a semistructured interview and clinical records. Comparative sex analysis were done via Student’s T and Mann-Whitney U tests for parametric and nonparametric continuous variables, chi-square and Fisher’s exact tests for unpaired categorical variables, and McNemar’s test for paired ones. The median diagnostic delay in women 7.5 (11.5) years is higher than men 4 (11) years, with a difference close to statistical significance (p = 0.053). A total of 30.2% of men received a first correct diagnosis of spondyloarthritis versus 11.1% of women (p = 0.016), indicating that men have higher probability of not having a misdiagnosis of spondyloarthritis (odds ratio = 3.5; 1.3–9). Eleven different health services referred male patients to the rheumatology clinic but only six in the case of female. No sex differences were detected in patients’ manifestations of back pain at onset. However, medical records registered differences (women 44.4%, men 82.1%; p < 0.001). There were differences between patients (women 57.7%, men 35.2%; p = 0.008) and medical records in peripheral signs/symptoms at onset (women 55.6%, men 17.9%; p < 0.001). The few differences of self-reported manifestations between both sexes with spondyloarthritis as compared with their clinical records (more axial pain in men and more peripheral pain in women) suggests that the professionals’ annotations reflect what they expect according to Literature, which could explain the higher misdiagnosis and diagnostic delay in women with spondyloarthritis.

25 November 2022 in Arthritis Care & Research
Verified
Journal Article
Closed access
JBJosé‐Antonio Bernal
José‐Antonio Bernal
Mariano AndrésMariano Andrés
Mariano Andrés
SLSalvador López‐Salguero
Salvador López‐Salguero
VJVega Jovaní
Vega Jovaní
PVPaloma Vela‐Casasempere
Paloma Vela‐Casasempere
EPEliseo Pascual
Eliseo Pascual

1 July 2022 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
VJVega Jovaní
Vega Jovaní
ICIrene Calabuig
Irene Calabuig
MPMaria Luisa Peral-Garrido
Maria Luisa Peral-Garrido
ETErnesto Tovar-Sugrañes
Ernesto Tovar-Sugrañes
MLMaría-Del-Carmen López-González
María-Del-Carmen López-González
Mariano AndrésMariano Andrés
Mariano Andrés

1 April 2021 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
MBMar Blasco-Blasco
Mar Blasco-Blasco
ICIsabel Castrejon
Isabel Castrejon
VJVega Jovaní
Vega Jovaní
EPEliseo Pascual
Eliseo Pascual
MCMª Teresa Ruiz Cantero
Mª Teresa Ruiz Cantero
Objective: To determine whether the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Ankylosing Spondylitis Disease Activity Score (ASDAS) exhibited differences between women and men.Methods: We systematically searched MEDLINE, Embase, Web of Science, and other sources in English or Spanish from January 1, 1995, to July 31, 2020, to assess the differences according to sex in BASDAI and ASDAS. We performed a comparative analysis by sex using t test and mean difference by sex metaanalyses for BASDAI and ASDAS, as well as a random-effects model using the inverse-variance method.Results: Forty-one studies included BASDAI (6785 women, 12,929 men) and 16 of them included ASDAS (2046 women, 4403 men). Disease activity detected using BASDAI was significantly higher in women than in men (mean 4.9 vs 4.2, P = 0.02), whereas ASDAS did not detect differences between sexes (mean 2.8 women vs 2.8 men). In the metaanalyses, BASDAI detected significant differences between women and men (mean difference = 0.55 [95% CI 0.46–0.65], P < 0.00001), but ASDAS did not identify significant mean difference between sexes (0.04, 95% CI –0.05 to 0.12], P = 0.38).Conclusion: The 2 most widely used indices of disease activity in spondyloarthritis (SpA) discriminate differently according to sex by their different evaluations of peripheral disease. The different components and weights in BASDAI and ASDAS influence their values. BASDAI may be affected by fatigue, and in predominantly peripheral manifestations such as enthesitis, ASDAS may not be sensitive enough to detect activity. This may represent a sex bias unfavorable to women, because peripheral SpA is more common in women than in men.

18 August 2020 in Journal of Medical Virology
Verified
Journal Article
Open access
PDF file
VJVega Jovaní
Vega Jovaní
EPEliseo Pascual
Eliseo Pascual
PVPaloma Vela
Paloma Vela
Mariano AndrésMariano Andrés
Mariano Andrés
We have read with interest the article by Saricaoglu EM et al 1 published in the recent issue of the Journal of Medical Virology. The authors diagnosed reactive arthritis in a 73 year old male patient after debut of polyarthritis in feet eight days after finishing treatment for COVID‐19. Although viral‐associated arthritis or a reactive arthritis should be considered in differential diagnosis, they do not describe if synovial fluid was analysed.